(Q113892449)

English

A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors

clinical trial

In more languages

default values for all languages

No label defined

No description defined

edit

Statements

instance of

clinical trial

0 references

title

A Single-arm, Open-label, Multicenter, Phase II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Subjects With Locally Advanced Unresectable or Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors (English)

0 references

start time

24 April 2020

0 references

end time

30 June 2021

0 references

number of participants

70

0 references

clinical trial phase

phase II clinical trial